Top Cell Encapsulation System Manufacturers 2026
Cell encapsulation system manufacturers develop equipment used to enclose biological cells within protective materials for research and therapeutic applications. With a focus on encapsulation precision, cell viability, process consistency and system compatibility, they support advanced biotechnology research and more reliable cell-based applications.

Advanced Encapsulation Systems: Supporting Consistent Cell Processing
Cell encapsulation technology is expanding the opportunities to develop and deliver next-generation therapies. It isolates living cells in a protective material, creating a controlled environment while allowing the passage of certain materials between the cells and the surrounding tissue. Examples of applications are regenerative medicine, tissue engineering and cell-based therapies. A manufacturer of cell encapsulation systems creates and produces equipment that makes it much simpler for controlled processing, consistent material handling and protection of sensitive cells.
Cell Encapsulation Systems Require More than Immune Protection
Cell therapies can appear promising in laboratory assays yet become difficult to assess after implantation. An early immune response may destroy transplanted cells before researchers can determine whether they produce the intended therapeutic substance. Encapsulation systems address that interference, but preventing immune attack is only part of the purchase decision. A barrier that also restricts nutrient delivery or the release of therapeutic molecules can defeat the purpose of protecting the cells. The device must support a credible experiment, not merely keep its contents separated from surrounding tissue.

Cellular therapy treatment has been around for 50 years, getting its start with hematopoietic stem cell transplant bone marrow transplant (HSCT) as the treatment of blood cancers. In 2017, a new type of treatment called Chimeric Antigen Receptor T-cell (CAR-T) therapy, has been effective for many patients with far advanced relapsed and refractory blood cancers, and may be used increasingly in the future to supplant BMT. CAR-T uses a patient’s reengineered T-cells to seek and destroy cancer cells in the patient’s body. UPHS, like many other established BMT centers, had to prepare by building the infrastructure to onboard these therapies. Development of a CAR-T therapy infrastructure has created issues that were unique from BMT, including the high dollar cost of the therapy that puts increased risk on centers when delivering this care to patients.
